Skip to main content
. Author manuscript; available in PMC: 2014 Aug 17.
Published in final edited form as: Synapse. 2010 Apr;64(4):301–312. doi: 10.1002/syn.20718

Figure 3.

Figure 3

Biodistribution of [11C]-3-PHNO in control animals (n=3, clear bars) or following pre-treatment with unlabelled PHNO (1mg/kg i.v. n=4, grey bars) or raclopride (2mg/kg i.v.; n=4, black bars). Data is presented as uptake units (mean±SD) and was collected 60 minutes following administration of ~280μCi [11C]-3-PHNO i.v. Brain regions are coded as follows: 1: striata; 2: olfactory bulbs; 3: olfactory tubercles; 4: thalamus; 5: hypothalamus; 6: prefrontal cortex; 7: somatosensory cortex; 8: entorhinal cortex 9: hippocampus; 10: inferior colliculi; 11: superior colliculi; 12: medulla with pons; 13: cerebellum. Pre-treatment with unlabelled PHNO or raclopride significantly reduced (p<0.05) [11C]-3-PHNO uptake units in all brain regions except the entorhinal cortex and hippocampus.